Research Program
Research Program
Infection, Inflammation and Cancer
Coordinator Dr. Tim Waterboer
Approximately one in five incidences of cancer is triggered by an infection. Most of them are caused by viruses, but bacteria and parasites may also play an important role in cancer development. Thus, the research program “Infection and Cancer” investigates which pathogens are able to promote cancer, the mechanisms that underlie these cancer processes, and how the human body protects itself against these pathogens. The work within the research program is based on four major aspects:
- Basic research on the molecular mechanisms of infection and cancer
- Development of new diagnostic approaches for cancer-relevant pathogens
- Establishment of innovative treatment approaches for infection-related cancers
- Development of vaccines and antivirals against cancer-relevant pathogens and viruses of relevance for patients undergoing immune-depleting cancer therapy
Research projects in this program cover the following areas:
- Pathogens and Cancer:
- Analysis of pathogens for which there is a clear or suspected association to cancer
- Identification of previously unknown pathogens in tumors and other chronic diseases
- Mechanisms of interactions between pathogens and patient
- Role of inflammatory processes in the course of cancer development
- Diagnosis and epidemiology of infection-related cancers
- Development of new approaches for diagnosis using blood or tissue samples, based on detection of specific antibodies or the genetic material of the pathogen.
- Investigation of the relationship between the presence of certain pathogens in medical samples and the development of Tumors
- Development of novel therapeutic approaches
- Viruses as direct inhibitors of tumor growth
- Establishment of viruses and non-viral vectors for tumor and gene therapy
- Development and application of novel vaccines and antivirals
- Establishment of novel and improvements on existing pre-clinical models for vaccine development
- Development of vaccines against Epstein-Barr virus
- Follow-up studies of vaccinations against cervical cancer (human papilloma virus vaccine) and expansion of vaccine application range in clinics
- Development of antivirals against clinically relevant human noroviruses
Divisions
- Tumor Virology Prof. Dr. Dr. h. c. Ralf Bartenschlager (in ch.)
- Infections and Cancer Epidemiology Dr. Tim Waterboer
- Viral Transformation Mechanisms Prof. Dr. Frank Rösl
- Pathogenesis of Virus Associated Tumors Prof. Dr. Dr. Henri-Jacques Delecluse
- Immunotherapy and Immunoprevention PD Dr. Dr. Angelika Riemer
- Virus-associated Carcinogenesis Prof. Dr. Dr. h. c. Ralf Bartenschlager
- Chronic Inflammation and Cancer Prof. Dr. Mathias Heikenwälder
- Microbiome and Cancer Prof. Dr. Eran Elinav
- Clinical Cooperation Unit Applied Tumor Biology Prof. Dr. med. Magnus von Knebel Doeberitz
- Clinical Cooperation Unit Virotherapy Prof. Dr. Dr. Guy Ungerechts
Other Units and Groups
- Helmholtz University Junior Research Group Cell Plasticity and Epigenetic Remodeling Dr. Darjus Tschaharganeh
- Junior Research Group Experimental Hepatology, Inflammation and Cancer Dr. Dr. Michael Dill
- Research Group Tumorvirus-specific Vaccination Strategies apl. Prof. Dr. Martin Müller
- Research Group Mammalian Cell Cycle Control Mechanisms Prof. Dr. Ingrid Hoffmann
- Research Group Molecular Therapy of Virus-Associated Cancers Prof. Dr. Felix Hoppe-Seyler
- Research Group DNA Vectors Dr. Richard Harbottle
- Research Group Episomal-Persistent DNA in Cancer- and Chronic Diseases Dr. Timo Bund